Metosyn Fapg

Fluocinide, the active ingredient in Metosyn Fapg, is a topical corticosteroid presented as a topical formulation for dermatological use. It reduces inflammation and allergic reactions in various skin conditions.

GNH USA supplies Metosyn Fapg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluocinide is a potent topical corticosteroid used to manage inflammatory skin disorders.

- Psoriasis: reduces plaque thickness, erythema and scaling. - Atopic dermatitis: alleviates itching, redness and swelling. - Contact dermatitis: diminishes allergic skin reactions and inflammation. - Lichen planus: controls lesions and associated discomfort.

Fluocinide may cause local and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Pruritus or mild itching. - Dryness or flaking of the skin. - Erythema or mild redness. - Folliculitis or acne‑like eruptions. - Telangiectasia (visible small blood vessels).

Serious or Rare Side Effects: - Skin atrophy or thinning. - Secondary bacterial, fungal or viral infections. - Systemic adrenal suppression with extensive use. - Hypersensitivity reactions such as urticaria or angioedema. - Delayed wound healing. - Hyperglycaemia in susceptible individuals.

When using Fluocinide, follow safety measures to minimise risks.

- Application area: limit use to affected skin only and avoid healthy skin. - Duration of therapy: restrict continuous use to the shortest period required. - Sensitive sites: avoid face, intertriginous areas and mucous membranes unless directed. - Occlusion: do not cover treated skin with airtight dressings unless prescribed. - Pediatric use: exercise caution in children due to higher per‑kg absorption. - Systemic absorption: monitor for signs of adrenal suppression with extensive application. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluocinide can interact with other agents that affect corticosteroid activity or skin integrity.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Immunosuppressants (e.g., tacrolimus): heightened risk of infection. - Live vaccines: possible reduced vaccine efficacy. - Antifungal or antibacterial topical agents: may increase local irritation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied to the same area: increased irritation risk. - Herbal preparations with corticosteroid‑like activity: potential additive effects. - Phototherapy: may enhance skin thinning. - Diabetic medications: monitor blood glucose if extensive skin absorption occurs.